Skip to main content

MoneyWorks4Me

Biocon - Quaterly Results

05 Nov 2026 Evaluate
The revenue for the September 2026 quarter is pegged at Rs. 6305.00 millions, about 8.09% up against Rs. 5833.00 millions recorded during the year-ago period.The company has announced a 29.34% increase in its profits to Rs . 917.00  millions for the  quarter ended September 2026 compared to Rs. 709.00 millions in the corresponding quarter in the previous year.The company reported a degrowth in operating Profit to 1799.00 millions from 1867.00 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202609 202509 % Var 202609 202509 % Var 202603 202503 % Var
Sales 6305.00 5833.00 8.09 12550.00 11204.00 12.01 23464.00 22426.00 4.63
Other Income 907.00 1338.00 -32.21 1555.00 1951.00 -20.30 3197.00 2423.00 31.94
PBIDT 1799.00 1867.00 -3.64 3055.00 2686.00 13.74 5458.00 4181.00 30.54
Interest 219.00 672.00 -67.41 392.00 1234.00 -68.23 1424.00 2369.00 -39.89
PBDT 1580.00 1195.00 32.22 2663.00 1452.00 83.40 1883.00 7887.00 -76.13
Depreciation 382.00 338.00 13.02 766.00 671.00 14.16 1373.00 1278.00 7.43
PBT 1198.00 857.00 39.79 1897.00 781.00 142.89 510.00 6609.00 -92.28
TAX 281.00 148.00 89.86 458.00 155.00 195.48 138.00 516.00 -73.26
Deferred Tax 28.00 116.00 -75.86 38.00 112.00 -66.07 18.00 11.00 63.64
PAT 917.00 709.00 29.34 1439.00 626.00 129.87 372.00 6093.00 -93.89
Equity 8148.00 6685.00 21.88 8148.00 6685.00 21.88 8105.00 6003.00 35.02
PBIDTM(%) 28.53 32.01 -10.86 24.34 23.97 1.54 23.26 18.64 24.77
Peers
Company Name CMP
Sun Pharma. Inds. 1880.90
Dr. Reddys Labs. 1377.00
Cipla 1393.00
Lupin 1980.00
Zydus Lifesciences 1191.00
View more..